About Transgene Biotek Limited.
Data last updated: 14 July 2026
Transgene Biotek Limited. is a public limited company based in Ida Bollaram, Telangana, India. It specialises in biotechnology, a part of the broader life sciences sector. Incorporated on 01 March 1990, the company has been in operation for over 36 years.
Registered with ROC Hyderabad under CIN L85195TG1990PLC011065. Listed on BSE: 526139.
Capital: an authorised share capital of ₹76 Cr and a paid-up capital of ₹75.77 Cr. It is led by directors including Kollipara Koteswara Rao and Sujana Kadiam.
Last AGM: 30 December 2025. Financial statements filed for year ended 31 March 2025. Office: Plot No:69 & 70 Ida Bollaram Sangareddy District., Telangana, India – 502325.
As per BSE-filed consolidated financials for FY 2026, the company reported a revenue of ₹21.12 Lakh, a decline of 18.99% compared to the previous year. The net worth stands at ₹8.38 Cr (down 16.48% YoY). Total assets are valued at ₹143.66 Cr (down 0.3% YoY).
Its group structure includes 1 subsidiary.
The company is associated with 1 brand - Transgene Biotek. As per MCA filings, the company has open charges of ₹12.57 Cr and satisfied charges of ₹9.88 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website transgenebiotek.com.
-
EmailLocked
-
TelephoneLocked
-
Website
-
Social MediaLocked
-
Registered AddressPlot No:69 & 70 Ida Bollaram Sangareddy District., Telangana, India – 502325
-
IndustryLife Sciences, Biotechnology
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Transgene Biotek Limited.
Transgene Biotek Limited. has one previous CIN (Corporate Identification Number): L85195AP1990PLC011065. The current CIN is L85195TG1990PLC011065, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L85195TG1990PLC011065 | Current |
| L85195AP1990PLC011065 | Previous |
Associated Brands with Transgene Biotek Limited.
Transgene Biotek Limited. operates one associated brand: Transgene Biotek. These brands represent Transgene Biotek Limited.'s diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Immunotherapies and drug delivery solutions for cancer are developed. | transgenebiotek.com |
Competitors & Alternatives of Transgene Biotek Limited.
Brands and companies operating in the same space as Transgene Biotek Limited. include Jazz Pharmaceuticals, Spark Therapeutics, BridgeBio and 6 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Jazz Pharmaceuticals
|
Novel biopharmaceutical medicines are developed for unmet medical needs. | Dublin, Ireland, Ireland | 2003 |
Spark Therapeutics
|
Gene therapies for rare diseases including retinal dystrophies are developed. | Philadelphia, United States, United States | 2013 |
BridgeBio
|
Therapeutics for genetic diseases are developed through targeted interventions. | Palo Alto, United States, United States | 2015 |
Syndax
|
Targeted therapies for cancer treatment are developed. | Waltham, United States, United States | 2005 |
Insitro
|
An AI-enabled platform is developed for infectious disease treatment. | San Francisco, United States, United States | 2018 |
Alnylam
|
RNA interference-based therapeutics are developed for multiple disorders. | Cambridge, United States, United States | 2002 |
Revolution Medicines
|
Cancer therapies are developed using selective pathway inhibitors. | Redwood City, United States, United States | 2014 |
Blueprint Medicines
|
Selective kinase inhibitors are developed for genomically defined cancers. | Cambridge, United States, United States | 2008 |
ATAI
|
A biopharmaceutical company accelerating innovative mental health treatments. | Munich, Germany, Germany | 2018 |
Business Activity of Transgene Biotek Limited.
Transgene Biotek Limited. is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details for Transgene Biotek Limited.
Turnover contribution percentages and historical activity changes require an active report plan.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Auditor Details of Transgene Biotek Limited.
Transgene Biotek Limited. is audited by VASAVI & CO (ICAI peer reviewed, certificate valid till 2026-11-30) for the financial year 2026, as reported in its BSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| VASAVI & CO (ICAI peer reviewed, certificate valid till 2026-11-30) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Transgene Biotek Limited.
Transgene Biotek Limited. is currently managed by 4 directors, with 8 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Kollipara Koteswara Rao | Managing Director | 04 Mar 2020 | 6 Years 5 Months | Current |
|
Sujana Kadiam
Also directs:
Transgene Biotek Limited.
|
Director | 17 Apr 2015 | 11 Years 4 Months | Current |
|
Santhosh Kumar
Also directs:
Transgene Biotek Limited., Sanghi Spinners India Limited
|
Director | 12 Nov 2019 | 6 Years 9 Months | Current |
|
Swetha Marri
Also directs:
Transgene Biotek Limited.
|
Director | 03 Jun 2020 | 6 Years 2 Months | Current |
Financials of Transgene Biotek Limited. FY 2026 filings available
Transgene Biotek Limited. reported revenue of ₹21.12 Lakh (down 18.99% YoY) for FY 2026.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2022 |
|---|---|---|---|---|
| Revenue from Operations | ₹21.12 Lakh | ₹26.07 Lakh | ₹23.29 Lakh | ₹8.67 Lakh |
| Other Income | ₹14.99 Lakh | ₹78.35 Lakh | ₹18.27 Lakh | ₹21.25 Lakh |
| Total Income | ₹36.11 Lakh | ₹1.04 Cr | ₹41.56 Lakh | ₹29.92 Lakh |
| Cost of Materials Consumed | ₹0 | ₹0 | ₹6,000 | ₹2.21 Lakh |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹0 | ₹0 | ₹0 | -₹6.8 Lakh |
| Employee Benefit Expense | ₹14.73 Lakh | ₹30.78 Lakh | ₹31.12 Lakh | ₹28.79 Lakh |
| Finance Costs | ₹1.06 Cr | ₹24.3 Lakh | ₹12.91 Lakh | ₹22.68 Lakh |
| Depreciation & Amortisation | ₹19.91 Lakh | ₹9.32 Lakh | ₹9.23 Lakh | ₹9.92 Cr |
| Other Expenses | ₹60.74 Lakh | ₹1.08 Cr | ₹53.97 Lakh | ₹30.9 Lakh |
| Total Expenses | ₹2.01 Cr | ₹1.72 Cr | ₹1.07 Cr | ₹10.7 Cr |
| Profit Before Exceptional Items & Tax | -₹1.65 Cr | -₹67.6 Lakh | -₹65.73 Lakh | -₹10.4 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | -₹1.65 Cr | -₹67.6 Lakh | -₹65.73 Lakh | -₹10.4 Cr |
| Total Tax Expense | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Profit | -₹1.65 Cr | -₹67.6 Lakh | -₹65.73 Lakh | -₹10.4 Cr |
| attributable to Owners | ₹0 | - | - | ₹0 |
| attributable to NCI | ₹0 | - | - | ₹0 |
| Other Comprehensive Income | ₹0 | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | -₹1.65 Cr | -₹67.6 Lakh | -₹65.73 Lakh | -₹10.4 Cr |
| EBITDA (computed) | -₹39.36 Lakh | -₹33.98 Lakh | -₹43.59 Lakh | -₹25.17 Lakh |
| Basic EPS | ₹-0.22 | ₹-0.09 | ₹0.09 | ₹-1.37 |
| Diluted EPS | ₹-0.22 | ₹-0.09 | ₹0.09 | ₹-1.37 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2022 |
|---|---|---|---|---|
| Total Assets | ₹143.66 Cr | ₹144.09 Cr | ₹142.33 Cr | ₹147.1 Cr |
| Non-current Assets | ₹142.63 Cr | ₹142.83 Cr | ₹141.22 Cr | ₹146.4 Cr |
| Current Assets | ₹1.03 Cr | ₹1.26 Cr | ₹1.11 Cr | ₹69.85 Lakh |
| Property, Plant & Equipment | ₹3.09 Cr | ₹3.29 Cr | ₹1.67 Cr | ₹1.85 Cr |
| Inventories | ₹3.4 Lakh | ₹3.4 Lakh | ₹3.39 Lakh | ₹9.46 Lakh |
| Trade Receivables | ₹84,000 | ₹84,000 | ₹83,000 | ₹84,400 |
| Cash & Equivalents | ₹6.07 Lakh | ₹28.43 Lakh | ₹76,000 | ₹1.51 Lakh |
| Equity (Net Worth) | ₹8.38 Cr | ₹10.03 Cr | ₹10.71 Cr | ₹17.38 Cr |
| Equity Share Capital | ₹75.77 Cr | ₹75.77 Cr | ₹75.77 Cr | ₹75.77 Cr |
| Borrowings (Non-current) | ₹6.8 Cr | ₹6.1 Cr | ₹5.08 Cr | ₹4.77 Cr |
| Borrowings (Current) | ₹10.34 Cr | ₹8.42 Cr | ₹8.92 Cr | ₹7.24 Cr |
| Total Debt (computed) | ₹17.14 Cr | ₹14.52 Cr | ₹14 Cr | ₹12.01 Cr |
| Current Liabilities | ₹13.26 Cr | ₹12.74 Cr | ₹11.14 Cr | ₹9.21 Cr |
| Total Liabilities | ₹135.28 Cr | ₹134.06 Cr | ₹131.62 Cr | ₹129.72 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2022 |
|---|---|---|---|---|
| Operating Cash Flow | -₹1.13 Lakh | ₹1.2 Cr | -₹57.41 Lakh | ₹8.61 Lakh |
| Investing Cash Flow | ₹15 Lakh | -₹1.7 Cr | -₹17.54 Lakh | -₹9.5 Lakh |
| Financing Cash Flow | -₹36.23 Lakh | ₹78.04 Lakh | ₹75.21 Lakh | ₹0 |
| Capital Expenditure | ₹0 | ₹0 | ₹0 | ₹0 |
| Free Cash Flow (computed) | -₹1.13 Lakh | ₹1.2 Cr | -₹57.41 Lakh | ₹8.61 Lakh |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | -₹22.36 Lakh | ₹27.67 Lakh | ₹26,000 | -₹89,500 |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹5.45 Lakh | ₹5.45 Lakh | ₹5.28 Lakh | ₹4.95 Lakh | ₹7.65 Lakh | ₹7.65 Lakh | ₹5.85 Lakh | ₹4.92 Lakh |
| Other Income | ₹14.99 Lakh | ₹0 | ₹0 | ₹0 | ₹4.38 Lakh | ₹4.48 Lakh | ₹4.38 Lakh | ₹65.19 Lakh |
| Total Income | ₹20.44 Lakh | ₹5.45 Lakh | ₹5.28 Lakh | ₹4.95 Lakh | ₹12.03 Lakh | ₹12.13 Lakh | ₹10.23 Lakh | ₹70.11 Lakh |
| Cost of Materials Consumed | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Employee Benefit Expense | ₹3.38 Lakh | ₹3.31 Lakh | ₹3.31 Lakh | ₹4.72 Lakh | ₹6.34 Lakh | ₹8.15 Lakh | ₹8.19 Lakh | ₹8.09 Lakh |
| Finance Costs | ₹27.68 Lakh | ₹27.35 Lakh | ₹26.43 Lakh | ₹24.55 Lakh | ₹19.12 Lakh | ₹1.73 Lakh | ₹1.73 Lakh | ₹1.73 Lakh |
| Depreciation & Amortisation | ₹4.98 Lakh | ₹4.98 Lakh | ₹4.98 Lakh | ₹4.98 Lakh | ₹2.35 Lakh | ₹2.32 Lakh | ₹2.32 Lakh | ₹2.32 Lakh |
| Other Expenses | ₹30.1 Lakh | ₹7.18 Lakh | ₹9.4 Lakh | ₹14.07 Lakh | ₹55.53 Lakh | ₹8.73 Lakh | ₹5.33 Lakh | ₹38.03 Lakh |
| Total Expenses | ₹66.14 Lakh | ₹42.82 Lakh | ₹44.12 Lakh | ₹48.32 Lakh | ₹83.34 Lakh | ₹20.93 Lakh | ₹17.57 Lakh | ₹50.17 Lakh |
| Profit Before Exceptional Items & Tax | -₹45.7 Lakh | -₹37.37 Lakh | -₹38.84 Lakh | -₹43.37 Lakh | -₹71.31 Lakh | -₹8.8 Lakh | -₹7.34 Lakh | ₹19.94 Lakh |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | -₹45.7 Lakh | -₹37.37 Lakh | -₹38.84 Lakh | -₹43.37 Lakh | -₹71.31 Lakh | -₹8.8 Lakh | -₹7.34 Lakh | ₹19.94 Lakh |
| Total Tax Expense | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Profit | -₹45.7 Lakh | -₹37.37 Lakh | -₹38.84 Lakh | -₹43.37 Lakh | -₹71.31 Lakh | -₹8.8 Lakh | -₹7.34 Lakh | ₹19.94 Lakh |
| attributable to Owners | ₹0 | ₹0 | - | - | - | - | - | ₹0 |
| attributable to NCI | ₹0 | ₹0 | - | - | - | - | - | ₹0 |
| Other Comprehensive Income | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | -₹45.7 Lakh | -₹37.37 Lakh | -₹38.84 Lakh | -₹43.37 Lakh | -₹71.31 Lakh | -₹8.8 Lakh | -₹7.34 Lakh | ₹19.94 Lakh |
| EBITDA (computed) | -₹13.04 Lakh | -₹5.04 Lakh | -₹7.43 Lakh | -₹13.84 Lakh | -₹49.84 Lakh | -₹4.75 Lakh | -₹3.29 Lakh | ₹23.99 Lakh |
| Basic EPS | ₹-0.06 | ₹-0.05 | ₹-0.05 | ₹-0.06 | ₹-0.09 | ₹-0.01 | ₹-0.01 | ₹0.03 |
| Diluted EPS | ₹-0.06 | ₹-0.05 | ₹-0.05 | ₹-0.06 | ₹-0.09 | ₹-0.01 | ₹-0.01 | ₹0.03 |
| Segment · Q2 FY25 (latest quarter) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| NIL | ₹0 | ₹0 | ₹0 | ₹0 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2022 |
|---|---|---|---|---|
| Revenue from Operations | ₹21.12 Lakh | ₹26.07 Lakh | ₹23.9 Lakh | ₹8.67 Lakh |
| Other Income | ₹14.99 Lakh | ₹78.35 Lakh | ₹18.27 Lakh | ₹21.25 Lakh |
| Total Income | ₹36.11 Lakh | ₹1.04 Cr | ₹42.17 Lakh | ₹29.92 Lakh |
| Cost of Materials Consumed | ₹0 | ₹0 | ₹6,000 | ₹2.21 Lakh |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹0 | ₹0 | ₹0 | -₹6.8 Lakh |
| Employee Benefit Expense | ₹14.73 Lakh | ₹30.78 Lakh | ₹31.12 Lakh | ₹28.79 Lakh |
| Finance Costs | ₹1.06 Cr | ₹24.3 Lakh | ₹12.91 Lakh | ₹22.68 Lakh |
| Depreciation & Amortisation | ₹19.91 Lakh | ₹9.32 Lakh | ₹9.23 Lakh | ₹9.92 Cr |
| Other Expenses | ₹60.74 Lakh | ₹1.08 Cr | ₹53.97 Lakh | ₹30.9 Lakh |
| Total Expenses | ₹2.01 Cr | ₹1.72 Cr | ₹1.07 Cr | ₹10.7 Cr |
| Profit Before Exceptional Items & Tax | -₹1.65 Cr | -₹67.6 Lakh | -₹65.12 Lakh | -₹10.4 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | -₹1.65 Cr | -₹67.6 Lakh | -₹65.12 Lakh | -₹10.4 Cr |
| Total Tax Expense | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Profit | -₹1.65 Cr | -₹67.6 Lakh | -₹65.12 Lakh | -₹10.4 Cr |
| Other Comprehensive Income | ₹0 | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | -₹1.65 Cr | -₹67.6 Lakh | -₹65.12 Lakh | -₹10.4 Cr |
| EBITDA (computed) | -₹39.36 Lakh | -₹33.98 Lakh | -₹42.98 Lakh | -₹25.17 Lakh |
| Basic EPS | ₹-0.22 | ₹-0.09 | ₹0.09 | ₹-1.37 |
| Diluted EPS | ₹-0.22 | ₹-0.09 | ₹0.09 | ₹-1.37 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2022 |
|---|---|---|---|---|
| Total Assets | ₹33.76 Cr | ₹34.18 Cr | ₹32.44 Cr | ₹37.22 Cr |
| Non-current Assets | ₹32.75 Cr | ₹32.95 Cr | ₹31.34 Cr | ₹36.53 Cr |
| Current Assets | ₹1.02 Cr | ₹1.24 Cr | ₹1.1 Cr | ₹69.01 Lakh |
| Property, Plant & Equipment | ₹3.09 Cr | ₹3.29 Cr | ₹1.67 Cr | ₹1.85 Cr |
| Inventories | ₹3.4 Lakh | ₹3.4 Lakh | ₹3.39 Lakh | ₹9.46 Lakh |
| Trade Receivables | ₹0 | ₹0 | ₹0 | ₹0 |
| Cash & Equivalents | ₹6.07 Lakh | ₹28.43 Lakh | ₹76,000 | ₹1.52 Lakh |
| Equity (Net Worth) | -₹9.2 Cr | -₹7.57 Cr | -₹6.87 Cr | -₹19.7 Lakh |
| Equity Share Capital | ₹75.77 Cr | ₹75.77 Cr | ₹75.77 Cr | ₹75.77 Cr |
| Borrowings (Non-current) | ₹6.8 Cr | ₹6.1 Cr | ₹5.08 Cr | ₹4.77 Cr |
| Borrowings (Current) | ₹10.34 Cr | ₹8.42 Cr | ₹8.92 Cr | ₹7.25 Cr |
| Total Debt (computed) | ₹17.14 Cr | ₹14.52 Cr | ₹14 Cr | ₹12.02 Cr |
| Current Liabilities | ₹13.14 Cr | ₹12.62 Cr | ₹11.04 Cr | ₹9.1 Cr |
| Total Liabilities | ₹42.96 Cr | ₹41.75 Cr | ₹39.31 Cr | ₹37.42 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2022 |
|---|---|---|---|---|
| Operating Cash Flow | -₹1.13 Lakh | ₹1.2 Cr | -₹56.8 Lakh | ₹8.61 Lakh |
| Investing Cash Flow | ₹15 Lakh | -₹1.7 Cr | -₹17.54 Lakh | -₹9.5 Lakh |
| Financing Cash Flow | -₹36.23 Lakh | ₹78.04 Lakh | ₹75.21 Lakh | ₹0 |
| Capital Expenditure | ₹0 | ₹0 | ₹0 | ₹0 |
| Free Cash Flow (computed) | -₹1.13 Lakh | ₹1.2 Cr | -₹56.8 Lakh | ₹8.61 Lakh |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | -₹22.36 Lakh | ₹27.67 Lakh | ₹87,000 | -₹89,500 |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹5.45 Lakh | ₹5.45 Lakh | ₹5.28 Lakh | ₹4.95 Lakh | ₹7.65 Lakh | ₹7.65 Lakh | ₹5.85 Lakh | ₹4.92 Lakh |
| Other Income | ₹14.99 Lakh | ₹0 | ₹0 | ₹0 | ₹4.38 Lakh | ₹4.38 Lakh | ₹4.38 Lakh | ₹65.19 Lakh |
| Total Income | ₹20.44 Lakh | ₹5.45 Lakh | ₹5.28 Lakh | ₹4.95 Lakh | ₹12.03 Lakh | ₹12.03 Lakh | ₹10.23 Lakh | ₹70.11 Lakh |
| Cost of Materials Consumed | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Employee Benefit Expense | ₹3.38 Lakh | ₹3.31 Lakh | ₹3.31 Lakh | ₹4.72 Lakh | ₹6.34 Lakh | ₹8.15 Lakh | ₹8.19 Lakh | ₹8.09 Lakh |
| Finance Costs | ₹27.68 Lakh | ₹27.35 Lakh | ₹26.43 Lakh | ₹24.55 Lakh | ₹19.12 Lakh | ₹1.73 Lakh | ₹1.73 Lakh | ₹1.73 Lakh |
| Depreciation & Amortisation | ₹4.98 Lakh | ₹4.98 Lakh | ₹4.98 Lakh | ₹4.98 Lakh | ₹2.35 Lakh | ₹2.32 Lakh | ₹2.32 Lakh | ₹2.32 Lakh |
| Other Expenses | ₹30.1 Lakh | ₹7.18 Lakh | ₹9.4 Lakh | ₹14.07 Lakh | ₹55.53 Lakh | ₹8.73 Lakh | ₹5.33 Lakh | ₹38.03 Lakh |
| Total Expenses | ₹66.14 Lakh | ₹42.82 Lakh | ₹44.12 Lakh | ₹48.32 Lakh | ₹83.34 Lakh | ₹20.93 Lakh | ₹17.57 Lakh | ₹50.17 Lakh |
| Profit Before Exceptional Items & Tax | -₹45.7 Lakh | -₹37.37 Lakh | -₹38.84 Lakh | -₹43.37 Lakh | -₹71.31 Lakh | -₹8.9 Lakh | -₹7.34 Lakh | ₹19.94 Lakh |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | -₹45.7 Lakh | -₹37.37 Lakh | -₹38.84 Lakh | -₹43.37 Lakh | -₹71.31 Lakh | -₹8.9 Lakh | -₹7.34 Lakh | ₹19.94 Lakh |
| Total Tax Expense | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Profit | -₹45.7 Lakh | -₹37.37 Lakh | -₹38.84 Lakh | -₹43.37 Lakh | -₹71.31 Lakh | -₹8.9 Lakh | -₹7.34 Lakh | ₹19.94 Lakh |
| Other Comprehensive Income | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | -₹45.7 Lakh | -₹37.37 Lakh | -₹38.84 Lakh | -₹43.37 Lakh | -₹71.31 Lakh | -₹8.9 Lakh | -₹7.34 Lakh | ₹19.94 Lakh |
| EBITDA (computed) | -₹13.04 Lakh | -₹5.04 Lakh | -₹7.43 Lakh | -₹13.84 Lakh | -₹49.84 Lakh | -₹4.85 Lakh | -₹3.29 Lakh | ₹23.99 Lakh |
| Basic EPS | ₹-0.06 | ₹-0.05 | ₹-0.05 | ₹-0.06 | ₹-0.09 | ₹0.00 | ₹-0.01 | ₹0.03 |
| Diluted EPS | ₹-0.06 | ₹-0.05 | ₹-0.05 | ₹-0.06 | ₹-0.09 | ₹0.00 | ₹-0.01 | ₹0.03 |
| Segment · Q2 FY25 (latest quarter) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| NIL | ₹0 | ₹0 | ₹0 | ₹0 |
Shareholding Pattern of Transgene Biotek Limited.
As per the shareholding pattern filed with BSE for the quarter ended Mar 2026, promoters hold 23.64%, retail and other public shareholders hold 76.36% of Transgene Biotek Limited.. The company had 13,767 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 23.64% | 23.64% | 23.64% | 23.64% | 23.64% | 23.64% |
| Public | 76.36% | 76.36% | 76.36% | 76.36% | 76.36% | 76.36% |
| Mar 2026 | Mar 2025 | Mar 2024 | |
|---|---|---|---|
| Promoters | 23.64% | 23.64% | 23.64% |
| Public | 76.36% | 76.36% | 76.36% |
| Promoter change (YoY, %pts) | +0.00 | +0.00 | - |
Group Structure of Transgene Biotek Limited.
Transgene Biotek Limited. has 1 subsidiary company. This group structure data is as of FY 2023. The corporate group structure reflects Transgene Biotek Limited.'s business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|---|---|
| Peroral Bio Private Limited | U24230TG2020PTC147169 | - |
Showing major subsidiaries. Total: 1.
Charges & Borrowings of Transgene Biotek Limited.
| Date | Lender | Amount | Status |
|---|---|---|---|
| 11 Apr 2025 | Others | ₹1.5 Cr | Open |
| 30 Jan 2025 | Others | ₹6 Cr | Open |
| 08 Apr 2010 | Department of Biotechnology | ₹5.07 Cr | Open |
| 30 Jul 2008 | Ge Capital Services India | ₹8.63 Lakh | Satisfied |
| 23 May 2007 | Union Bank of India | ₹3.92 Cr | Satisfied |
Total charge records: 10 View all charges
Employees and EPFO Compliance at Transgene Biotek Limited.
View historical data on people associated with Transgene Biotek Limited., including employment history and EPFO contributions.
Employee and EPFO history for Transgene Biotek Limited.
Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
GST Compliance of Transgene Biotek Limited.
GST registrations and filing compliance for Transgene Biotek Limited.
State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
Credit Ratings, Litigation & Regulatory Alerts for Transgene Biotek Limited.
Credit ratings, litigation, and regulatory alerts for Transgene Biotek Limited.
Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Transgene Biotek Limited.
MSME payment history for Transgene Biotek Limited.
Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Transgene Biotek Limited.
Corporate group structure for Transgene Biotek Limited.
Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Transgene Biotek Limited.
MCA filings and documents for Transgene Biotek Limited.
Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Recent Activity on Transgene Biotek Limited.
Recent News on Transgene Biotek Limited.
Frequently Asked Questions about Transgene Biotek Limited.
Transgene Biotek Limited. is an active public limited company in the life sciences sector based in Ida Bollaram, Telangana, India. It was incorporated on 01 March 1990 (36+ years old) and is registered under CIN L85195TG1990PLC011065. Listed on BSE: 526139.
Transgene Biotek Limited. reported revenue of ₹21.12 Lakh for FY 2026 (down 18.99% YoY) based on consolidated BSE filings.
The current directors of Transgene Biotek Limited. are:
- Kollipara Koteswara Rao - Managing Director
- Sujana Kadiam - Director
- Santhosh Kumar - Director
- Swetha Marri - Director
The primary industry of Transgene Biotek Limited. is life sciences. The company specifically operates in biotechnology. The company is currently active in this sector.
Yes. Transgene Biotek Limited. is listed on BSE with code 526139.
Transgene Biotek Limited. can be reached at the registered office: Plot No:69 & 70 Ida Bollaram Sangareddy District, Telangana, India – 502325, or through the website transgenebiotek.com.